The British Association for the Study of the Liver is a multi-disciplinary society with around 900 members composed of interested individuals from clinical medicine, clinical and basic research and allied professions.
The British Association for the Study of the Liver aims to disseminate research findings and clinical expertise, to promote opportunities for collaboration in liver research, to provide a voice that can advise and interact with the media and advises policymakers.
Dr Luke Boulter (centre) winner of the BASL Dame Sheila Sherlock Prize Lecture in 2015, he is pictured here with his team David Wilson (left) and Ronan Mellin (right). The Prize Lecture took place this year at the Basic Science Retreat where Dr Boulter was presented with a crystal award and £1,000.
Dr Tom Bird winner of the BASL Andy Burroughs Young Investigator Award 2015. This is a new award given in honour of the late Professor Andrew Burroughs. Dr Bird presented a 30 minute lecture at the BLTG Meeting and was awarded a crystal award and £1,000.
For 20 years The PBC Foundation has been supporting people diagnosed and living with Primary Biliary Cholangitis. After BASL 2016 on 9–11 Sept PBC members and supporters were involved in the 'three peaks in three days challenge (Scafell, Snowdon, Ben Nevis).
PBC Foundation ‘three peaks challenge’ - Robert Mitchell-Thain, Dimitar Tonev & Andy Bailey, amongst others took part.
PBC Foundation ‘three peaks challenge’ - a similar event will follow BASL 2017 and we hope that BASL members will take part next year.
Find out more
Find out more about the work of our committee sub-groups and forums by clicking the logos below. These include The British Viral Hepatitis Group, British Association for the Study of the Liver Nurse Forum and the British Liver Transplant Group.
The British Viral Hepatitis aims to improve the management and study of patients with chronic viral liver disease, bringing together UK hepatologists, gastroenterologists, infectious disease physicians, virologists and interested epidemiologists.
British Association for the Study of the Liver Nurse Forum is a professional nursing organisation aiming to develop knowledge and understanding of liver disease, in order to improve the quality of patient care.
The BLTG (British Liver Transplant Group) was launched in 2014 to represent the professional interests of liver transplantation in the UK and promote strategic and academic development.
BASL ANNUAL MEETING, BLTG Transplant Meeting & BASLNF Meeting 2016
- to view this year's ABSTRACTS CLICK HERE.
BASL is a multi-disciplinary society with around 900 members composed of interested individuals from clinical medicine, clinical and basic research and allied professions. Your Annual subscription is used to organise the Annual Meeting held each September.
Members of BASL receive the following benefits:
- discounted registration rates for the annual meeting and other relevant meetings
- eligibility for the BASL Travel Awards (for members below status of Senior Lecturer or Consultant to allow presentation of high-quality UK liver research at International meetings, including the American Association for the Study of Liver Disease)
- eligibility for the prestigious Dame Sheila Sherlock Award (to an emerging researcher in the field of liver disease, for members below status of Senior Lecturer or consultant). Applications are usually submitted to the BASL Committee three months prior to the annual meeting - details are announced.
Click here to find out more about joining us.
Alcoholic hepatitis remains a difficult condition to treat with conflicting evidence as to its best management.
The recent STOPAH trial results have had a mixed reception among the gastroenterology and hepatology community and there is a variation in clinical management across the country. We would like to document this variation and determine how to improve care for this group of patients.
This short survey will take 5 minutes of your time.
To participate in the survey click > HERE.
Thank you for your time.
Dr Ashwin Dhanda, NIHR Academic Clinical Lecturer, Plymouth Hospitals NHS Trust
Dr Stephen Atkinson, MRC Clinical Research Training Fellow, Imperial College London
Prof Mark Thursz, Professor of Hepatology, Imperial College NHS Trust
The combination of sofosbuvir plus ribavirin (RBV) is effective and tolerable in elderly HCV genotype two (G2) patients, a new Japanese study reported.
Thirty-seven HCV G2 patients aged 75 or older ,and 19 aged under 75 were treated with sofosbuvir and weight-based dose of RBV. The older group included more women, and had more history of hepatocellular carcinoma, lower serum albumin (ALB) level, lower haemoglobin (Hb) concentration, lower estimated glomerular filtration rate (eGFR), and a higher fibrosis-4 index.
Forty-one patients were evaluated for SVR at 12 weeks after the end of therapy (SVR12); of them, all but one completed the treatment scheduled for 12 weeks. The older group had a lower SVR12 rate than the younger group (81.3% versus 96.0%, respectively).
Although the Hb concentration and eGFR were significantly lower in the older group throughout the clinical course, all patients in this group completed the 12-week treatment with a gradual increase of serum ALB level.
The researchers noted that although the drug combination is tolerable and beneficial in patients aged over 75, intensive management of anaemia by dose reduction of RBV is necessary, which could lead to a low SVR12 rate compared to patients under 75.
Safety, tolerability, and efficacy of sofosbuvir plus ribavirin in elderly patients infected with hepatitis C virus genotype 2. Nishida N, Kono M, Minami T et al. Dig Dis. 2016;34(6):632-639 Epub 2016 Oct 17.
HIV patients co-infected with HBV or HCV and who are receiving anti-retroviral therapy (ART) are at an increased risk of non-Hodgkin lymphoma (NHL).
This was the conclusion by the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), which studied 52,479 treatment-naive patients of whom 1,339 had chronic HBV and 7,506 had HCV. A total of 40,219 later started ART. The median follow-up was 13 months for treatment-naïve patients and 50 months for those receiving ART.
A total of 252 treatment-naïve patients and 310 ART treated patients developed NHL, with incidence rates of 219 and 168 cases per 100,000 person-years, respectively. The hazard ratios for NHL with HBV and HCV infection were 1.33 and 0.67, respectively, in treatment-naive patients and 1.74 and 1.73, respectively, in ART treated patients.
Chronic hepatitis B and C virus infection and risk for non-Hodgkin lymphoma in HIV-infected patients: a cohort study. Wang Q, De Luca A, Smith C et al. Ann Intern Med. 2016 Oct 18 [Epub ahead of print]
A new animal study has looked at the relative safety of four anti-HBV drugs against HBV, with respect to kidney function and toxicity.
Researchers at Novartis Institutes for BioMedical Research, Basel, administered telbivudine, tenofovir, adefovir or entecavir to male Spraque-Dawley rats once daily for four weeks by oral gavage at about 10 and 25-40 times the human equivalent dose. Main assessments included markers of renal toxicity in urine, magnetic resonance imaging (MRI) of kidney function, histopathology and electron microscopic examination.
Administration of adefovir at 11 mg/kg and 28mg/kg for four weeks caused functional and morphological kidney alterations in a time- and dose-dependent manner, affecting mainly the proximal tubules and suggesting a mechanism of toxicity related to mitochondrial degeneration/depletion.
For the low dose of 300mg/kg of tenofovir, minor kidney effects such as nuclear enlargement in the tubular epithelium, and hyaline droplets accumulation were detected, which was also observed for the low dose (11mg/kg) of adefovir. No assessments could be done at the higher dose of 600/1,000mg/kg tenofovir due to gastrointestinal tract toxicity, which prevented treatment of the animals for longer than one week.
Entecavir at 1mg/kg and 3mg/kg and telbivudine at 600 mg/kg and 1,600mg/kg caused no toxicologically relevant effects on the kidney.
Comparative renal safety assessment of the hepatitis B drugs, adefovir, tenofovir, telbivudine and entecavir in rats. Uteng M, Mahl A, Beckmann N et al. Toxicol Sci. 2016 Oct 13 [Epub ahead of print]
Responding to the ruling made today in the Scottish courts in relation to minimum unit pricing in Scotland, Professor Sir Ian Gilmore, chair of the Alcohol Health Alliance, said:
"We welcome this court ruling, and hope to see minimum unit pricing speedily implemented in Scotland. Now is the time to act, even if the global alcohol producers, prioritising commercial interests over Scotland’s health, try to delay further by another appeal.
Now is also the time for England and Wales to follow suit and introduce MUP. The UK government committed to introducing MUP in 2012, and the public support the measure. Government-commissioned research estimates that in the first year following the implementation of MUP in England, there would be nearly 140 fewer crimes per day.
MUP leaves pub prices untouched, and targets the cheap alcohol which is preferentially consumed by children and dependent drinkers. Recent AHA research has found that alcohol is being sold for as little as 16p per unit, with 3 litre bottles of white cider, which contain the same amount of alcohol as 22 shots of vodka, available for just £3.49.
MUP would also be of greatest benefit to those on low income, with 8 out of 10 lives saved coming from the lowest income groups, and greater harm reductions felt by these groups. The government has spoken of its commitment to even out life chances, and MUP would go a long way in furthering this agenda."
For more information visit the AHA website > here.
Research released today shows there is an abundance of high strength alcohol sold for pocket money prices in shops and supermarkets across the UK.
A review of alcohol prices in a range of retailers found products like high strength white ciders, which are predominantly drunk by dependent and underage drinkers, available for as little as 16p per unit.
This means that for the cost of a standard off-peak cinema ticket it is possible to buy almost seven and a half litres of high strength white cider, containing as much alcohol as 53 shots of vodka.
The findings are released today in a report by the Alcohol Health Alliance UK (AHA) (Download Cheap alcohol the price we pay AHA Oct 2016.pdf), a group of medical royal colleges, alcohol organisations and health bodies. The report argues that recent cuts in alcohol taxes allow supermarkets to sell alcohol at rock bottom prices, but have done little to benefit pubs and their customers.
Chair of the Alcohol Health Alliance (AHA), leading liver doctor and former President of the Royal College of Physicians, Professor Sir Ian Gilmore said:
"In spite of a government commitment to tackle cheap, high-strength alcohol, these products are still available at pocket money prices. Harmful drinkers and children are still choosing the cheapest products: predominantly white cider and cheap vodka."
"We need to make excessively cheap alcohol less affordable through the tax system, including an increase in cider duty. It's not right that high strength white cider is taxed at a third of the rate for strong beer."
"In addition, we need minimum unit pricing. This would target the cheap, high strength products drunk by harmful drinkers whilst barely affecting moderate drinkers, and it would leave pub prices untouched. In fact, pubs could benefit from minimum unit pricing, as it would prevent the proliferation of cheap alcohol in our supermarkets."
"It's time the government took action and made all high strength alcohol less attractive to vulnerable drinkers."
Each year there are almost 23,000 deaths and more than one million hospital admissions related to alcohol in England and Government figures estimate that alcohol harm costs UK society more than £21billion.
The report, Cheap alcohol: the price we pay, warns that, unless action is taken on the availability of cheap alcohol, harms associated with alcohol consumption will continue to rise, increasing the burden on the NHS and public services.
For further information, please contact Matt Chorley, the AHA's Policy and Communications Officer, at firstname.lastname@example.org or on 0203 075 1726.
A new review suggests that people with psychiatric diseases may be at an increased risk of HIV/HCV co-infection
The authors, from the University of Barcelona, found that the prevalence of HCV infection among HIV-infected patients is high ranging from 50% to 90%. Patients with psychiatric diseases have also an increased risk for HIV/HCV co-infection.
The most effective strategy to decrease HCV-related morbidity and mortality in co-infection is to achieve viral eradication. Although psychiatric symptoms often appear during antiviral treatment and may be associated with the use of interferon-alpha, recent evidence suggests that many patients with comorbid mental and substance use disorders can be treated safely.
Recent data indicate that interferon-alpha-induced psychiatric side effects have a similar prevalence in HIV/HCV co-infected patients to mono-infected patients and they can be managed and even prevented successfully with psychopharmacological strategies in the frame of a multidisciplinary team. New antivirals offer interferon-free therapies for this specific population.
Mental disorders in HIV/HCV coinfected patients under antiviral treatment for hepatitis C. Martin-Subero M, Diez-Quevedo C. Psychiatry Res. 2016 Sep 26; 246:173-181 Epub ahead of print]
The combination of elbasvir and grazoprevir, with or without ribavirin, was effective in HCV patients failed by previous treatment, a large international study reported.
The study, at 65 centres in Europe, Asia, and Central and North America, assessed the effects of 12 or 16 weeks of a once daily tablet of elbasvir plus grazoprevir, with or without twice-daily ribavirin, in patients with HCV genotype one, four or six. There were 420 patients, of whom 35% had cirrhosis and 64% had a null or partial response to peg-interferon and ribavirin.
With 12 weeks of treatment, an SVR12 was achieved by 92.4% of patients given elbasvir and grazoprevir and 94.2% of patients given elbasvir and grazoprevir with ribavirin.
With 16 weeks of treatment, SVR12 was achieved by 92.4% of patients given elbasvir and grazoprevir and 98.1% of patients given elbasvir and grazoprevir with ribavirin.
Among patients treated for 12 weeks without ribavirin, virologic failure occurred in 6.8%, none, and 12.5% of patients with HCV genotype 1a, 1b, or four infection, respectively.
Also among patients given elbasvir and grazoprevir for 12 weeks, virologic failure occurred in none of the patients infected with HCV genotype 1, and 7.5% of those with genotype 4.
Among patients treated for 16 weeks who received ribavirin, there were no incidences of virologic failure. The treatment was generally well tolerated.
Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Kwo P, Gane E, Peng CY et al. Gastroenterology. 2016 Oct 5 [Epub ahead of print]
Venue: Hallam Conference Centre, 44 Hallam St, London, W1W 6JJ
The theme for the meeting is Viral Hepatitis: State of the Art Review on Hepatitis C and will cover:
- The potential for eradication
- Debate: re-infection in MSM – to treat or not to treat?
- State of the art: Treatment
Download a draft programme > Download Published Programme BVHG meeting 4th November 2016.pdf
REGISTER TODAY - > click HERE
Meetings are free to BASL / BVHG Members.
For non-members a charge of £45 will apply.
CPD points have been applied for.
We thank our BVHG sponsors for this meeting:
Premier sponsors - AbbVie, Bristol-Myers Squibb, Gilead and Key sponsors - MSD.
Venue: Hallam Conference Centre, 44 Hallam St, London, W1W 6JJ
To view the programme click here > Download Published School of Viral Hepatology Programme Nov 16.pdf
The School will join with the main BVHG Meeting from 12:00 for the Symposium sponsored by AbbVie followed by lunch.
REGISTER TODAY - > click HERE.
Meetings are free to BASL / BVHG Members.
For non-members a charge of £45 will apply.
We thank our School Series sponsors for this meeting:
Premier sponsors - Gilead and Norgine
The Liver Meeting® will be held at the John B. Hynes Veterans Memorial Convention Center in the heart of downtown Boston from Friday, November 11, 2016 - 12:30 to Tuesday, November 15, 2016 - 1:30.
AASLD is working hard to prepare and make 2016 a banner year – there are lots of exciting changes designed to enhance your experience and offer you more flexibility than ever before. This must-attend event gathers hepatologists from around the world to exchange the latest research, discuss new developments in treatment outcomes, and network with other experts in the field.
To read more visit the meeting website > here.
The 2016 Medical Council on Alcohol (MCA) Symposium, ‘Alcohol and health harm; what can doctors, nurses and other professionals do?’, will take place on 16th November at the Royal College of Surgeons, London.
In this symposium, they will focus on the ways in which health professionals from different disciplines, sectors and specialties can act to reduce these harms. It will cover approaches including brief interventions in different settings, primary care and commissioning, inequalities and public health, addiction medicine and accident and emergency.
For more details > click here to visit the MCA website.
The Gastroenterology Symposium in 2016 centres around the role of environmental factors in the pathogenesis and treatment of gastrointestinal and liver disease.
To read more and to view the programme and to find out how to register visit the Royal College of Physicians of Edinburgh website > here.
The meeting times are from 9 am – 5 pm and the venue is the Royal College of Physicians, 9 Queen Street, Edinburgh, EH2 1JQ, Scotland, UK
Should you have any questions please contact: Anne Fairbairn, Education Coordinator email@example.com .
BHIVA in collaboration with BVHG are delighted to announce the third Hepatology Highlights Meeting of 2016.
The event is free to attend and takes place on the evening of Thursday 24th November between 17:45 - 20:15, at the Radisson Blu Hotel, Birmingham and covers the latest updates in the treatment of HIV/Hepatitis Co-infection.
Programme – a provisional programme is available to view > HERE
Registration – on line registration is now open, to register click > HERE
Please note that places are limited and will be allocated, in principle, on a first-come, first-served basis.
2 CPD accreditation points have been applied for.
For and on behalf of the British HIV Association (BHIVA) and the British Viral Hepatitis Group.
The International Viral Hepatitis Elimination 2016, which will be held from 2 - 3 December 2016 at the historical West-Indisch Huis in Amsterdam, the Netherlands.
The objective of this meeting is to enhance elimination of viral hepatitis worldwide from the perspective of the medical community. This independent meeting will address obstacles on the elimination of viral hepatitis along with strategies for success.
BASL members can claim a 25% discount with the following registration discount code: ELIMEND.
Please note that this discount code only applies to the academia fees.
To view the preliminary programme click > HERE.
Join the International Viral Hepatitis Elimination Meeting 2016 by visiting the website > HERE.
Frontiers In Pregnancy - Related Liver Disease: Defining Interventions To Improve Outcome - Institute of Hepatology, London
View the Programme here > Download Frontiers in Pregnancy Related Liver Disease Programme.pdf
The Frontiers meeting will be free of charge.
If you are interested in registering please get in touch with Leslie McMurtry: firstname.lastname@example.org .
Further information will follow here next week.
Join BASL Ward Membership Today - £100 per annum for up to 5 members per ward.
Ward membership benefits include; access to the Nurse e-learning toolkits on the BASL website, reduced fees at BASL Events including the Nurses Day at the Annual Meeting in September.
To find out how to apply click here
The BASL Nurse Toolkits were developed following conversations with nurse specialists. These and a later email survey identified training needs to help nurses meet the liver nurse competencies. To access the Learning Toolkits sign in as a BASL Member and click on Manage Account